CanToo is passionate about funding groundbreaking cancer research. Through the support of our participants and donors, we’re able to back early-career researchers who are making groundbreaking discoveries. One of these researchers is Dr. Vasilios Panagopoulos, whose recent work on multiple myeloma is providing hope for new treatment possibilities.
Dr. Panagopoulos and his team at South Australian Health and Medical Research Institute, University of Adelaide have identified a promising new treatment strategy by targeting an enzyme called myeloperoxidase (MPO). Inhibiting MPO has shown significant results in pre-clinical models, reducing both the number and size of tumours. While this research is still in its early stages, these findings represent a critical step forward in exploring MPO as a potential treatment for multiple myeloma in humans.
Although more research is needed, these initial studies are a promising start and provide valuable insights into how MPO inhibition could lead to new therapies for blood cancer patients. Can Too Foundation is proud to be a part of this journey, funding the work of researchers like Dr. Panagopoulos, who are dedicated to finding breakthroughs that will improve lives.
This exciting discovery is just one example of how Can Too Foundation’s support is driving innovation in cancer research. If you’d like to learn more about our mission and the research we fund, click here.
The original research published by Dr Panagopolous and his team can be accessed for free here: doi.org/10.1111/bjh.19102
What is Multiple Myeloma?
Multiple myeloma is a specific type of blood cancer that affects plasma cells in bone marrow, which can lead to tumours and weaken the immune system. It can affect multiple places in the body including the spine, skull, pelvis, ribs, shoulders and hips. Current treatments are available, but there is a constant need for new approaches to improve patient outcomes, as only three in ten people with multiple myeloma will live beyond ten years of their diagnosis. In 2024, an estimated 1,207 Australians will die from multiple myeloma, with another 2,719 estimated to be diagnosed with the disease in the same year.Dr. Panagopoulos and his team at South Australian Health and Medical Research Institute, University of Adelaide have identified a promising new treatment strategy by targeting an enzyme called myeloperoxidase (MPO). Inhibiting MPO has shown significant results in pre-clinical models, reducing both the number and size of tumours. While this research is still in its early stages, these findings represent a critical step forward in exploring MPO as a potential treatment for multiple myeloma in humans.
Although more research is needed, these initial studies are a promising start and provide valuable insights into how MPO inhibition could lead to new therapies for blood cancer patients. Can Too Foundation is proud to be a part of this journey, funding the work of researchers like Dr. Panagopoulos, who are dedicated to finding breakthroughs that will improve lives.
This exciting discovery is just one example of how Can Too Foundation’s support is driving innovation in cancer research. If you’d like to learn more about our mission and the research we fund, click here.
The original research published by Dr Panagopolous and his team can be accessed for free here: doi.org/10.1111/bjh.19102
